论文部分内容阅读
目的:比较银杏磷脂胶囊与血脂康胶囊治疗高脂血症的临床疗效。方法:将60例高脂血症患者随机分为2组,分别服用血脂康胶囊和银杏磷脂胶囊。进行治疗前后对体重指数、总胆固醇、三酰甘油、高密度脂蛋白胆固醇、低密度脂蛋白胆固醇、脂蛋白(a)、C反应蛋白与纤维蛋白原比较。结果:与治疗前比较,2种药物均能明显降低总胆固醇、三酰甘油、低密度脂蛋白胆固醇、升高高密度脂蛋白胆固醇(P<0.05)、C反应蛋白与纤维蛋白原(P<0.01);与对照组比较,治疗组患者的脂蛋白(a)明显降低(P<0.05)。结论:银杏磷脂胶囊有调节血脂的作用,且降低脂蛋白(a)与纤维蛋白原的作用较血脂康强。
Objective: To compare the clinical efficacy of Ginkgo Phospholipid Capsule and Xuezhikang Capsule in the treatment of hyperlipidemia. Methods: 60 cases of hyperlipidemia were randomly divided into two groups, taking Xuezhikang capsules and ginkgo phospholipid capsules. Body mass index, total cholesterol, triglyceride, high density lipoprotein cholesterol, low density lipoprotein cholesterol, lipoprotein (a), C-reactive protein and fibrinogen were compared before and after treatment. Results: Compared with those before treatment, the two drugs significantly reduced total cholesterol, triglyceride, low density lipoprotein cholesterol, elevated high density lipoprotein cholesterol (P <0.05), C reactive protein and fibrinogen (P < 0.01). Compared with the control group, the lipoprotein (a) in the treatment group was significantly lower (P <0.05). Conclusion: Ginkgo Phospholipid Capsule has the effect of regulating blood lipid, and reducing the effect of lipoprotein (a) and fibrinogen compared with Xuezhikang.